Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.

MLA

Konstantinopoulos, Panagiotis A., et al. “Randomized Phase 2 Study of Gemcitabine with or without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival (OS) and Biomarker Analyses.” Journal of Clinical Oncology, vol. 41, June 2023, p. 5512. EBSCOhost, https://doi.org/10.1200/JCO.2023.41.16_suppl.5512.

APA

Konstantinopoulos, P. A., Lee, E. K., Cheng, S., Da Costa, A. A. B. A., Wahner Hendrickson, A. E., Gulhan, D., Kochupurakkal, B., Kolin, D., Kohn, E. C., Liu, J. F., Stover, E., Curtis, J., Sawyer, H., Polak, M., Chowdhury, D., Färkkilä, A., D’Andrea, A. D., Shapiro, G., & Matulonis, U. A. (2023). Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses. Journal of Clinical Oncology, 41, 5512. https://doi.org/10.1200/JCO.2023.41.16_suppl.5512

Chicago

Konstantinopoulos, Panagiotis A., Elizabeth Katherine Lee, SuChun Cheng, Alexandre Andre B. A. Da Costa, Andrea Elisabeth Wahner Hendrickson, Doga Gulhan, Bose Kochupurakkal, et al. 2023. “Randomized Phase 2 Study of Gemcitabine with or without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival (OS) and Biomarker Analyses.” Journal of Clinical Oncology 41 (June): 5512. doi:10.1200/JCO.2023.41.16_suppl.5512.